Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 1, 2025
Kraig Biocraft Laboratories Secures Four Registered Trademarks for SpydaSilk® Brand, to Advance Commercialization Strategy for Recombinant Spider Silk
GlobeNewswire
·
April 1, 2025
ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or the "Company"), a world leader in recombinant spider silk technology, today announced that it has secured four registered trademarks for …
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of …
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 1, 2025
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, …
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
·
April 1, 2025
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of …
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to …
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire
·
April 1, 2025
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation …
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
GlobeNewswire
·
April 1, 2025
CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a …
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
GlobeNewswire
·
April 1, 2025
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl …
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
GlobeNewswire
·
April 1, 2025
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in …
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
GlobeNewswire
·
April 1, 2025
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N.J., April 01, 2025 (GLOBE …
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
GlobeNewswire
·
April 1, 2025
124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare …
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
GlobeNewswire
·
April 1, 2025
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on …
Medicenna to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Codexis Appoints Cynthia Collins to Board of Directors
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s …
Le Système PA-100 AST de Sysmex : Révolutionner le diagnostic et le traitement des IU avec précision
GlobeNewswire
·
April 1, 2025
PARIS, 01 avr. 2025 (GLOBE NEWSWIRE) -- Le Système PA-100 AST de Sysmex redéfinit les normes de soins pour le diagnostic et le traitement des infections urinaires (IU). En associant une technologie nanofluidique de pointe à un antibiogramme rapide, le …
Sysmex’s PA-100 AST System: Revolutionising UTI diagnosis and treatment with precision
GlobeNewswire
·
April 1, 2025
PARIS, April 01, 2025 (GLOBE NEWSWIRE) -- Sysmex’s PA-100 AST System is redefining standard of care for diagnosing and treating urinary tract infections (UTIs). By combining cutting-edge nanofluidic technology with rapid antimicrobial susceptibility …
Teleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP)
GlobeNewswire
·
April 1, 2025
WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology …
ITM Appoints Dr. Celine Wilke as Chief Medical Officer
GlobeNewswire
·
April 1, 2025
Experienced leader in radiopharmaceutical drug development, regulatory, and clinical strategies will advance ITM’s broad pipeline and clinical development strategy Garching / Munich, Germany, April 01, 2025 – ITM Isotope Technologies Munich SE (ITM), a …
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
GlobeNewswire
·
April 1, 2025
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant …
Best Testosterone Supplement For Men Over 40 and 50: Testo Prime for For Muscle Gain & Erectile Dysfunction 2025 By (Testo Prime)
GlobeNewswire
·
April 1, 2025
GLASGOW, United Kingdom, April 01, 2025 (GLOBE NEWSWIRE) -- If you’re a man over 50, you have likely seen first-hand how your body changes as you get older. Working out feels like a chore, you seem to notice new aches and pains every day, and your libido …